News From NPR

Transcript

CELESTE HEADLEE, HOST:

This is TELL ME MORE from NPR News. I'm Celeste Headlee. Michel Martin is away. Coming up, for Sampson Davis, ending the health care crisis in America's inner cities isn't just a professional goal. It's a personal mission. He'll talk about serving the Newark, New Jersey neighborhoods where he grew up and his new book, "Living and Dying in Brick City."

Transcript

CELESTE HEADLEE, HOST:

And now we'll turn from New Jersey to Detroit, where tensions are really building around the public school system there. The U.S. Department of Education is looking into whether recent school closures have disproportionately hurt black and Latino students. Also, an emergency financial manager is shaking things up at Detroit Public Schools after getting some new authority from the state.

Here to explain is Jerome Vaughn, news director at member station WDET in Detroit. Welcome back, Jerome.

Transcript

CELESTE HEADLEE, HOST:

This is TELL ME MORE from NPR News. I'm Celeste Headlee. Michel Martin is away. Coming up, we'll talk about school takeovers and whether or not taking a drastic action like that really fixes broken schools. But first we'll bring you up to date on the latest political news. There is a lot going on both here and overseas - the debate over gun control, immigration, and a little saber rattling from North Korea.

Transcript

CELESTE HEADLEE, HOST:

Now it's time for a Wisdom Watch conversation. That's a part of the program where we talk to those who've made a difference with their work. Today we're talking with Clinton Galloway. He's the author of the book "Anatomy of a Hustle: Cable Comes to South Central L.A."

A decision by India's Supreme Court to reject Novartis AG's bid to patent a version of one cancer drug could lead to more exports of cheap medicine from that country to "poor people across the developing world," the BBC writes.

NPR's Julie McCarthy tells our Newscast Desk that the ruling, announced Monday, ends a six-year legal battle that has been closely watched by pharmaceutical firms, humanitarian aid organizations and generic drug manufacturers.

She adds that: